|
gracilioether F
|
C000600615 |
|
|
4-pentadecylbenzylphosphonic acid
|
C560360 |
|
|
5beta,19-epoxycucurbitane
|
C000600616 |
|
|
(Z)-ethyl 2-((1-(biphenyl-4-ylmethyl)indol-3-yl) methylene)-7-methyl-3-oxo-5-phenylthiazolo(3,2-a)pyrimidine-6-carboxylate
|
C560361 |
|
|
cystobactamid 919-2
|
C000600617 |
|
|
3-methoxy-1-oxa-2,7-diaza-7,10-ethanospiro(4.5)dec-2-ene
|
C560362 |
|
|
DRD2 protein, mouse
|
C000600618 |
|
|
heparosan
|
C560363 |
|
|
SBA-16
|
C000600619 |
|
|
pyrrolo(2,1-a)isoquinoline
|
C560364 |
|
|
Prokaryotic Initiation Factor-2
|
D039881 |
[The largest of the three prokaryotic initiation factors with a molecular size of approximately 80 kD. It functions in the transcription initiation process by promoting the binding of formylmethionine-tRNA to the P-site of the 30S ribosome and by preventing the incorrect binding of elongator tRNA to the translation initiation site.
] |
|
psilostachyin C
|
C560366 |
|
|
N-(4-trifluoromethylphenyl)retinamide
|
C560367 |
|
|
dinapinone A
|
C560368 |
|
|
monapinone A
|
C560369 |
|
|
Prolyl-Hydroxylase Inhibitors
|
D064800 |
[Compounds that inhibit the action of HYDROXYLASES that act on PROLINE to form HYDROXYPROLINE.
] |
|
Phospholipase A2 Inhibitors
|
D064801 |
[Compounds that inhibit or block the activity of a PHOSPHOLIPASE A2 enzyme.
] |
|
Urological Agents
|
D064804 |
[Drugs used in the treatment of urogenital conditions and diseases such as URINARY INCONTINENCE; PROSTATIC HYPERPLASIA; and ERECTILE DYSFUNCTION.
] |
|
Bunolol
|
D064805 |
[A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
] |
|
Dysbiosis
|
D064806 |
[Changes in quantitative and qualitative composition of MICROBIOTA. The changes may lead to altered host microbial interaction or homeostatic imbalance that can contribute to a disease state often with inflammation.
] |
